Appello Pharmaceuticals, Inc.

Quick facts

Phase 2 pipeline

• AP-472 · Psychiatry
  AP-472 is a small molecule that targets the serotonin receptor 5-HT2A.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Appello Pharmaceuticals, Inc. portfolio CI brief
• Appello Pharmaceuticals, Inc. pipeline updates RSS